Lipopolysaccharide-mediated chronic inflammation promotes tobacco carcinogen-induced lung cancer and determines the efficacy of immunotherapy

Chia-Hsin Liu,Zhong Chen,Kong Chen,Fu-Tien Liao,Chia-En Chung,Xiaoping Liu,Yu-Chun Lin,Phouthone Keohavong,George D Leikauf,Yuanpu Peter Di,George D. Leikauf

DOI: https://doi.org/10.1158/0008-5472.can-20-1994

IF: 11.2

2020-10-29

Cancer Research

Abstract:Chronic obstructive pulmonary disease (COPD) is an inflammatory disease that is associated with increased risk of lung cancer. <i>Pseudomonas aeruginosa</i> (PA) infections are frequent in patients with COPD, which increase lung inflammation and acute exacerbations. However, the influences of PA-induced inflammation on lung tumorigenesis and the efficacy of immune checkpoint blockade remain unknown. In this study, we initiated a murine model of lung cancer by treating FVB/NJ female mice with tobacco carcinogen nitrosamine 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone (NNK) alone or in combination with PA-lipopolysaccharide (LPS). LPS-mediated chronic inflammation induced T-cell exhaustion, increased the programmed cell death-1 (PD-1)/programmed cell death ligand-1 (PD-L1) axis, and enhanced NNK-induced lung tumorigenesis through an immunosuppressive microenvironment characterized by accumulation of myeloid-derived suppressive cells (MDSC) and regulatory T cells. Anti-PD-1 antibody treatment reduced tumors in NNK/LPS-treated mice with a 10-week LPS treatment but failed to inhibit tumor growth when LPS exposure was prolonged to 16 weeks. Anti-Ly6G antibody treatment coupled with depletion of MDSC alone reduced tumor growth; when combined with anti-PD-1 antibody, this treatment further enhanced antitumor activity in 16-week NNK/LPS-treated mice. Immune gene signatures from a human lung cancer dataset of PD-1 blockade were identified, which predicted treatment responses and survival outcome and overlapped with those from the mouse model. This study demonstrated that LPS-mediated chronic inflammation creates a favorable immunosuppressive microenvironment for tumor progression and correlates with the efficacy of anti-PD-1 treatment in mice. Immune gene signatures overlap with human and mouse lung tumors, providing potentially predictive markers for patients undergoing immunotherapy. SIGNIFICANCE: This study identifies an immune gene signature that predicts treatment responses and survival in patients with tobacco carcinogen-induced lung cancer receiving immune checkpoint blockade therapy.

oncology

What problem does this paper attempt to address?

The problem this paper attempts to address is to explore how chronic inflammation caused by Pseudomonas aeruginosa (PA) affects tobacco carcinogen-induced lung cancer development and to determine the impact of this inflammation on the efficacy of immune checkpoint inhibitors (such as anti-PD-1 antibodies). Specifically, the researchers established a mouse lung cancer model simulating the combined effects of smoking carcinogen (NNK) and chronic inflammation (LPS) to investigate the following key questions: 1. **How chronic inflammation promotes lung cancer development**: The researchers found that repeated LPS exposure significantly enhances NNK-induced lung cancer development, manifested by an increase in tumor number and size, as well as the accumulation of immunosuppressive cells (such as myeloid-derived suppressor cells MDSC and regulatory T cells Treg) in the tumor microenvironment. 2. **The impact of chronic inflammation on the efficacy of immunotherapy**: The researchers found that anti-PD-1 antibodies can effectively reduce lung cancer development at an early stage (10 weeks of LPS exposure), but the effect is significantly weakened in the long term (16 weeks of LPS exposure). This suggests that long-term chronic inflammation may lead to immunotherapy failure through other mechanisms (such as the accumulation of MDSC). 3. **The effectiveness of combination therapy strategies**: The researchers further found that a combination therapy regimen of anti-PD-1 antibodies and anti-Ly6G antibodies (used to deplete MDSC) can significantly inhibit tumor growth and improve therapeutic efficacy under 16 weeks of LPS exposure. 4. **Predictive value of immune gene signatures**: By analyzing immune gene signatures in human lung cancer datasets, the researchers found that these signatures can predict patients' responses to PD-1 blockade therapy and survival outcomes, consistent with the results in the mouse model. This provides potential biomarkers for selecting suitable patients for immunotherapy in clinical practice. In summary, this paper aims to reveal the role of chronic inflammation in lung cancer development and its impact on the efficacy of immunotherapy, and to explore effective combination therapy strategies to improve the efficacy of immunotherapy.

Lipopolysaccharide-mediated chronic inflammation promotes tobacco carcinogen-induced lung cancer and determines the efficacy of immunotherapy

Nicotine Enhances Invasion and Metastasis of Human Colorectal Cancer Cells Through the Nicotinic Acetylcholine Receptor Downstream P38 MAPK Signaling Pathway.

Author Correction: the Aryl Hydrocarbon Receptor Mediates Tobacco-Induced PD-L1 Expression and is Associated with Response to Immunotherapy.

WNT/β-catenin Signaling Regulates Cigarette Smoke-Induced Airway Inflammation Via the PPARδ/p38 Pathway

Smoker and non-smoker lung adenocarcinoma is characterized by distinct tumor immune microenvironments.

Chronic Obstructive Pulmonary Disease Alters Immune Cell Composition and Immune Checkpoint Inhibitor Efficacy in Non‐Small Cell Lung Cancer

Abstract LB046: Characterizing the role of inflammation-induced epigenetic alterations in modulating the immune microenvironment during lung cancer initiation

Promotion of Lung Cancer Progression by Copd-Like Chronic Inflammation in A Mouse Model

Similar programmed death ligand 1 (PD-L1) expression profile in patients with mild COPD and lung cancer

Inflammation mediated by gut microbiome alterations promotes lung cancer development and an immunosuppressed tumor microenvironment

Chronic NF-κB Activation Links COPD and Lung Cancer Through Generation of an Immunosuppressive Microenvironment in the Lungs.

Tobacco exposure primes the secretion of CCL21 positively associated with tertiary lymphoid structure and response to immunotherapy

Promotion of Lung Carcinogenesis by Chronic Obstructive Pulmonary Disease–Like Airway Inflammation in a K-ras–Induced Mouse Model

PD-L2 mediates tobacco smoking-induced recruitment of regulatory T cells via the RGMB/NFκB/CCL20 cascade

Accumulation of plasmacytoid dendritic cell is associated with a treatment response to DNA-damaging treatment and favorable prognosis in lung adenocarcinoma

Polymorphonuclear myeloid-derived suppressor cells and phosphatidylinositol-3 kinase gamma are critical to tobacco-mimicking oral carcinogenesis in mice

Tobacco smoking and cessation and PD-L1 inhibitors in non-small cell lung cancer (NSCLC): a review of the literature

Tumor-Activated Neutrophils Promote Lung Cancer Progression through the IL-8/PD-L1 Pathway

Nicotine Promotes the Development of Non-Small Cell Lung Cancer Through Activating LINC00460 and PI3K/Akt Signaling

Tumor necrosis factor links chronic obstructive pulmonary disease and K-ras mutant lung cancer through induction of an immunosuppressive pro-tumor microenvironment

Cigarette Smoke or Motor Vehicle Exhaust Exposure Induces PD-L1 Upregulation in Lung Epithelial Cells in COPD Model Rats